Login / Signup

Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development.

Kimia KardaniParya BasimiMehrshad FekriAzam Bolhassani
Published in: Expert review of clinical pharmacology (2020)
There is no effective FDA approved vaccine against the sexually transmitted viruses (STVs) except for HBV and HPV as prophylactic vaccines. Many attempts are underway to develop vaccines against these viruses. There are several approaches for improving prophylactic or therapeutic vaccines such as heterologous prime/boost immunization, delivery system, administration route, adjuvants, etc. In this line, further studies can be helpful for understanding the immunobiology of STVs in human. Moreover, development of more relevant animal models is a worthy goal to induce effective immune responses in humans.
Keyphrases
  • immune response
  • endothelial cells
  • hepatitis b virus
  • high grade
  • genetic diversity
  • dendritic cells
  • toll like receptor
  • liver failure
  • pluripotent stem cells
  • saccharomyces cerevisiae
  • drug administration